Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Marinus Pharma CS (NQ: MRNS )

16.44 USD +0.31 (+1.92%)
Official Closing Price Updated: 7:06 PM EST, Mar 3, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Marinus Pharma CS

< Previous 1 2 3 4 5 6 7 Next >
Marinus Pharmaceuticals Announces Pricing of Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS) (“Marinus” or the “Company”) announced the pricing of an underwritten public offering of 12,000,000 shares of common stock at a public offering price of... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Public Offering of Common Stock
Marinus Pharmaceuticals, Inc. (NASDAQ: MRNS), (“Marinus” or the “Company”) today announced that it intends to offer and sell 12,000,000 shares of its common stock in an underwritten public offering.... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Positive Ganaxolone Data in Women With Postpartum Depression
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy, depression and other... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Phase 2 Clinical Trial Data Show Long-term Effectiveness of Ganaxolone in Reducing Seizure Frequency in CDKL5 Deficiency Disorder Patients
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present Ganaxolone Clinical Trial Data in CDKL5 Deficiency Disorder and PCDH19-Related Epilepsy at AES
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Research Report Identifies Oil States International, Brightcove, Electronics for Imaging, Cirrus Logic, Innoviva, and Marinus Pharmaceuticals with Renewed Outlook — Fundamental Analysis, Calculating F
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Oil States International,... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Provides Business Update and Third Quarter 2018 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Names Dr. Rolando Gutíerrez-Esteinou as VP of Clinical Development and Pharmacovigilance
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced the... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Completes Enrollment in its Magnolia Postpartum Depression Study
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, announced it has... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Appoints Scott Braunstein, MD to its Board of Directors
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced the... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at the Baird Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today... 
From GlobeNewswire News Releases
Analysis: Positioning to Benefit within MannKind, Chimerix, Superior Energy Services, Marinus Pharmaceuticals, Airgain, and Eagle Pharmaceuticals — Research Highlights Growth, Revenue, and Consolidate
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of MannKind Corporation... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at Wedbush/PacGrow Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Provides Business Update and Second Quarter 2018 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Analysis: Positioning to Benefit within Marinus Pharmaceuticals, Valley National, BB&T, Cognizant Technology Solutions, Cinemark, and International Game Technology — Research Highlights Growth, Revenu
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Marinus Pharmaceuticals,... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Be Added to the Russell 2000 and Russell 3000 Index
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Initiates Pivotal Phase 3 Trial in Children with CDKL5 Deficiency Disorder
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(C)(4)
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”, “Marinus”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at Upcoming Investor Conferences
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (the “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at the UBS Global Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that... 
From GlobeNewswire News Releases
Consolidated Research: 2018 Summary Expectations for STORE Capital, Microvision, International Game Technology, McKesson, Marinus Pharmaceuticals, and Alnylam Pharmaceuticals — Fundamental Analysis, K
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of STORE Capital Corporation... 
From GlobeNewswire News Releases
Free Research Reports on These Biotech Stocks -- MannKind, Marinus Pharma, Mirati Therapeutics, and OncoSec Medical
If you want a free Stock Review on MNKD, MRNS, MRTX, and ONCS sign up now at www.wallstequities.com/registration. WallStEquities.com has initiated research coverage on MannKind Corp. (NASDAQ: MNKD),... 
From PR Newswire
Marinus Pharmaceuticals Provides Business Update and First Quarter 2018 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS) (“Marinus” or “Company”), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals to Present at the Barclays Global Healthcare Conference
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today announced that... 
From GlobeNewswire News Releases
Marinus Pharmaceuticals Provides Business Update and 2017 Financial Results
Marinus Pharmaceuticals, Inc. (Nasdaq:MRNS), a biopharmaceutical company dedicated to the development of innovative therapeutics to treat epilepsy and neuropsychiatric disorders, today provided a... 
From GlobeNewswire News Releases
Report: Developing Opportunities within Discovery Communications, Otonomy, Marinus Pharmaceuticals, Citizens Financial Group, Washington Prime Group, and The Charles Schwab — Future Expectations, Proj
In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Discovery Communications,... 
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.